GSK (LON:GSK) Stock Crosses Above Two Hundred Day Moving Average – Should You Sell?

Shares of GSK plc (LON:GSK) crossed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of GBX 1,973.11 and traded as high as GBX 2,009. GSK shares last traded at GBX 1,982.96, with a volume of 13,901,154 shares traded.

Analyst Upgrades and Downgrades

GSK has been the topic of several research reports. Citigroup cut their price objective on shares of GSK from GBX 2,250 to GBX 2,100 and set a “neutral” rating on the stock in a research report on Wednesday, May 6th. Jefferies Financial Group reiterated a “buy” rating and set a GBX 2,500 target price on shares of GSK in a report on Thursday, May 28th. Shore Capital Group reissued a “buy” rating on shares of GSK in a research note on Wednesday, March 25th. Berenberg Bank restated a “hold” rating and issued a GBX 2,000 price target on shares of GSK in a report on Thursday, March 26th. Finally, Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating and set a GBX 1,900 price objective on shares of GSK in a research report on Monday, June 8th. Two equities research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, GSK presently has an average rating of “Hold” and an average target price of GBX 2,034.29.

GSK Stock Performance

The stock’s 50-day moving average price is GBX 1,933.58 and its 200 day moving average price is GBX 1,973.11. The company has a debt-to-equity ratio of 106.74, a current ratio of 0.79 and a quick ratio of 0.73. The firm has a market cap of £79.53 billion, a P/E ratio of 13.95, a price-to-earnings-growth ratio of 1.24 and a beta of 0.29.

GSK (LON:GSK) last released its earnings results on Wednesday, April 29th. The company reported GBX 46.50 earnings per share for the quarter. The business had revenue of GBX 762.90 billion during the quarter. GSK had a net margin of 17.78% and a return on equity of 35.78%. As a group, equities analysts predict that GSK plc will post 175.980975 EPS for the current year.

Insider Buying and Selling at GSK

In other GSK news, insider Jeannie Lee acquired 802 shares of GSK stock in a transaction dated Monday, June 22nd. The stock was bought at an average cost of GBX 5,069 per share, for a total transaction of £40,653.38. Also, insider Vishal Sikka acquired 1,266 shares of the firm’s stock in a transaction dated Monday, June 22nd. The stock was bought at an average price of GBX 5,069 per share, with a total value of £64,173.54. In the last quarter, insiders have purchased 7,630 shares of company stock valued at $21,357,859. Corporate insiders own 0.31% of the company’s stock.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.